CVS Health Corporation (CVS)
Compared to Estimates, CVS Health (CVS) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for CVS Health (CVS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CVS Health Stock Surges as Q1 Results Handily Top Estimates
CVS Health (CVS) shares powered 9% higher before the bell Thursday after the pharmacy and healthcare giant's first-quarter results handily topped estimates.
CVS Health (CVS) Q1 Earnings and Revenues Beat Estimates
CVS Health (CVS) came out with quarterly earnings of $2.25 per share, beating the Zacks Consensus Estimate of $1.71 per share. This compares to earnings of $1.31 per share a year ago.
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
CVS tops estimates, hikes guidance as insurance business shows some improvement
CVS Health reported first-quarter revenue and profit that topped estimates and hiked its guidance, as its troubled insurance business showed some improvement during the period. The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per share.
Gear Up for CVS Health (CVS) Q1 Earnings: Wall Street Estimates for Key Metrics
Evaluate the expected performance of CVS Health (CVS) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
CVS Health (CVS) Earnings Expected to Grow: Should You Buy?
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health (CVS) Ascends But Remains Behind Market: Some Facts to Note
In the most recent trading session, CVS Health (CVS) closed at $65.45, indicating a +0.43% shift from the previous trading day.
CVS Soars 53% in Q1: Time to Buy the Stock Ahead of Earnings Release?
Caremark, CVS Health's PBM business, is expected to have continued to play a vital role in offsetting the rising cost of branded drugs during the first quarter.
2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs
The medical sector stocks, notably the health insurance carriers, took a major drubbing in 2024 as Medicare Advantage (MA) plans continued to drive higher utilization costs, eating away at profits. These rising costs are illustrated by the medical benefits ratio (MBR), benefits expense ratio (BER), medical care ratio (MCR) or medical loss ratio (MLR), which is the percentage of premiums used to pay for medical services.
CVS Health: Maybe The Right Investment At The Right Time
CVS Health Corporation surged 10% intraday and ended yesterday 6% higher, driven by a new CFO announcement and increased Medicare Advantage payments. Despite a challenging fiscal 2024, CVS is undervalued with strong growth potential, expecting 3.5% revenue growth and 6-11% EPS growth in 2025. CVS remains a solid investment due to its recession-resilient business model, low tariff impact, and trading below intrinsic value.
